Sidiropoulos Theodoros, Dovrolis Nikolas, Katifelis Hector, Michalopoulos Nikolaos V, Kokoropoulos Panagiotis, Arkadopoulos Nikolaos, Gazouli Maria
4th Department of Surgery, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.
Laboratory of Biology, Department of Basic Medical Sciences, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Biomedicines. 2024 May 8;12(5):1040. doi: 10.3390/biomedicines12051040.
Pancreatic cancer (PC) ranks as the seventh leading cause of cancer-related deaths, with approximately 500,000 new cases reported in 2020. Existing strategies for early PC detection primarily target individuals at high risk of developing the disease. Nevertheless, there is a pressing need to identify innovative clinical approaches and personalized treatments for effective PC management. This study aimed to explore the dysbiosis signature of the fecal microbiota in PC and potential distinctions between its Intraductal papillary mucinous neoplasm (IPMN) and pancreatic ductal adenocarcinoma (PDAC) phenotypes, which could carry diagnostic significance. The study enrolled 33 participants, including 22 diagnosed with PDAC, 11 with IPMN, and 24 healthy controls. Fecal samples were collected and subjected to microbial diversity analysis across various taxonomic levels. The findings revealed elevated abundances of Firmicutes and Proteobacteria in PC patients, whereas healthy controls exhibited higher proportions of Bacteroidota. Both LEfSe and Random Forest analyses indicated the microbiome's potential to effectively distinguish between PC and healthy control samples but fell short of differentiating between IPMN and PDAC samples. These results contribute to the current understanding of this challenging cancer type and highlight the applications of microbiome research. In essence, the study provides clear evidence of the gut microbiome's capability to serve as a biomarker for PC detection, emphasizing the steps required for further differentiation among its diverse phenotypes.
胰腺癌（PC）是癌症相关死亡的第七大主要原因，2020年报告的新病例约有50万例。现有的早期胰腺癌检测策略主要针对疾病高发风险个体。然而，迫切需要确定创新的临床方法和个性化治疗方案，以实现胰腺癌的有效管理。本研究旨在探索胰腺癌患者粪便微生物群的失调特征，以及其导管内乳头状黏液性肿瘤（IPMN）和胰腺导管腺癌（PDAC）表型之间的潜在差异，这些差异可能具有诊断意义。该研究招募了33名参与者，包括22名被诊断为PDAC的患者、11名IPMN患者和24名健康对照者。收集粪便样本，并在不同分类水平上进行微生物多样性分析。研究结果显示，胰腺癌患者中厚壁菌门和变形菌门的丰度升高，而健康对照者中拟杆菌门的比例更高。线性判别分析效应大小（LEfSe）和随机森林分析均表明，微生物群有潜力有效区分胰腺癌患者和健康对照者的样本，但无法区分IPMN和PDAC样本。这些结果有助于增进目前对这种具有挑战性的癌症类型的了解，并突出了微生物组研究的应用。本质上，该研究提供了明确证据，证明肠道微生物群有能力作为胰腺癌检测的生物标志物，强调了在其不同表型之间进一步区分所需的步骤。
